Lucid Diagnostics
Lucid Diagnostics is a medical diagnostics company dedicated to revolutionizing cancer prevention through innovative, non-invasive technologies. Their mission is to enable early detection and treatment of esophageal precancer, thereby preventing its progression to lethal cancer. They develop and commercialize advanced molecular diagnostic tests, such as the EsoGuard DNA test, which detects esophageal precancer and cancer in a simple office-based visit without the need for endoscopy. The company is committed to improving patient outcomes through early diagnosis, research, and collaboration with clinicians and healthcare providers.
Industries
Nr. of Employees
medium (51-250)
Lucid Diagnostics
Products
Non‑endoscopic esophageal cell collection device (swallowable capsule with inflatable balloon)
A swallowable capsule that deploys a textured inflatable balloon to collect circumferential surface cells from the distal esophagus and then inverts to protect the sample during retrieval, enabling unsedated office‑based sampling.
Targeted DNA methylation diagnostic test for esophageal precancer (central lab assay)
A laboratory diagnostic test that evaluates methylation at multiple targeted genomic locations using bisulfite conversion and targeted NGS to identify epigenetic signatures associated with Barrett's esophagus and esophageal adenocarcinoma; intended as an office‑based screening or triage test to endoscopy.
Non‑endoscopic esophageal cell collection device (swallowable capsule with inflatable balloon)
A swallowable capsule that deploys a textured inflatable balloon to collect circumferential surface cells from the distal esophagus and then inverts to protect the sample during retrieval, enabling unsedated office‑based sampling.
Targeted DNA methylation diagnostic test for esophageal precancer (central lab assay)
A laboratory diagnostic test that evaluates methylation at multiple targeted genomic locations using bisulfite conversion and targeted NGS to identify epigenetic signatures associated with Barrett's esophagus and esophageal adenocarcinoma; intended as an office‑based screening or triage test to endoscopy.
Services
Central laboratory testing for esophageal precancer
Laboratory diagnostic service that performs targeted DNA methylation analysis on collected esophageal cell samples and returns a positive/negative report indicating detection of epigenetic changes consistent with precancer or cancer.
Provisioning and support for office‑based cell collection
Supply of a swallowable capsule device and clinician resources to perform office‑based distal esophageal cell collection without endoscopy, including training and materials for sample protection and transport.
Mobile and event‑based screening services
Coordination and execution of high‑volume community and occupational screening events using mobile testing units and staffed collection teams for targeted populations.
Insurance billing and patient financial assistance services
Direct billing to medical insurance carriers, management of claims, and administration of a financial assistance program and payment plans to reduce out‑of‑pocket cost for patients.
Central laboratory testing for esophageal precancer
Laboratory diagnostic service that performs targeted DNA methylation analysis on collected esophageal cell samples and returns a positive/negative report indicating detection of epigenetic changes consistent with precancer or cancer.
Provisioning and support for office‑based cell collection
Supply of a swallowable capsule device and clinician resources to perform office‑based distal esophageal cell collection without endoscopy, including training and materials for sample protection and transport.
Mobile and event‑based screening services
Coordination and execution of high‑volume community and occupational screening events using mobile testing units and staffed collection teams for targeted populations.
Insurance billing and patient financial assistance services
Direct billing to medical insurance carriers, management of claims, and administration of a financial assistance program and payment plans to reduce out‑of‑pocket cost for patients.
Expertise Areas
- Non‑endoscopic esophageal screening
- Molecular diagnostics (DNA methylation assays)
- Clinical study design and registry generation
- Analytical validation of diagnostic assays
Key Technologies
- Targeted next‑generation sequencing (targeted NGS)
- DNA methylation analysis (bisulfite conversion)
- Swallowable balloon‑based esophageal cell collection
- Copy number alteration (CNA) analysis and somatic mutation detection (e.g., TP53)